Navigation Links
Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)

ABBOTT PARK, Ill., June 4 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and AstraZeneca announced today that they have entered into an agreement for AstraZeneca to co-promote Abbott's TRILIPIX(R) (fenofibric acid), a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote TRILIPIX alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.

"Abbott's portfolio of lipid therapies is designed to help physicians manage a patient's total lipid profile," said Jeffrey Stewart, divisional vice president, Primary Care, Abbott. "With AstraZeneca's established presence in the cardiovascular space, this agreement allows Abbott to expand visibility and education of TRILIPIX among physicians whose patients may benefit from this medication."

"Part of AstraZeneca's corporate strategy is to establish successful external collaborations. AstraZeneca has a long-standing commitment to cardiovascular health and has an established presence in the cholesterol market. This agreement allows us to further strengthen our presence with physicians by including TRILIPIX as an offering to physicians for patients with dyslipidemia," said Jim Helm, vice president, cardiovascular, AstraZeneca US. "With clinical data to support its use in helping certain patients with mixed dyslipidemia to manage all three key lipids, TRILIPIX is another important therapeutic option we can now offer physicians."

TRILIPIX is a prescription medicine that is used along with diet to lower triglycerides and LDL (bad) cholesterol, and increase HDL (good) cholesterol. TRILIPIX is also used along with diet to lower triglycerides and increase HDL cholesterol in people who are at high risk of heart disease and are taking a statin medicine to control their LDL cholesterol. TRILIPIX has not been shown to prevent heart attacks or stroke more than a statin alone.

TRILIPIX should not be taken by people with liver, gallbladder, or severe kidney disease or by nursing mothers. People should tell their healthcare providers about all the medicines they take. Blood tests are needed before and during treatment with TRILIPIX to check for liver problems. A healthcare provider should be contacted if serious side effects such as unexplained muscle pain, tenderness, or weakness develop. The risk of these side effects may be higher when TRILIPIX is used with a statin. Other serious side effects may include abdominal pain, nausea, or vomiting.

About the Agreement

This agreement is the second co-promotion agreement between AstraZeneca and Abbott. In August of 2008, the companies announced a non-exclusive agreement for Abbott to co-promote AstraZeneca's CRESTOR(R) alongside AstraZeneca in the United States.

Important Safety Information About TRILIPIX(R) (fenofibric acid)

TRILIPIX should not be taken by people with liver, gallbladder, or severe kidney disease, nursing mothers, or those allergic to any product ingredient. Unexplained muscle pain, tenderness, or weakness, particularly when occurring with tiredness and fever, may be a sign of a serious side effect and should be reported to a healthcare provider right away. Rarely, muscle-related problems can cause kidney damage and can be fatal. The risk of these side effects may be increased when TRILIPIX is used with a statin. Patients should tell their healthcare provider about all the medicines they take. Blood tests should be performed before and during treatment with TRILIPIX to check for liver or kidney problems. Patients should contact their healthcare provider if they experience abdominal pain, nausea, or vomiting while taking TRILIPIX. These may be signs of inflammation of the gallbladder or pancreas. Women who are pregnant should not take statins and should talk with their healthcare provider about TRILIPIX if they are pregnant or may become pregnant. The most common side effects with TRILIPIX include headache, heartburn, nausea, muscle aches, and increases in muscle or liver enzymes that are measured by blood tests. Full Prescribing Information is available at Visit or call Abbott Medical Information at 1-800-633-9110 for more information about TRILIPIX.

About AstraZeneca

AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business.

For more information visit

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

SOURCE Abbott; AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Beard and Brooke Bennett are collaborating with brands across various categories through traditional ... influential figures make up an elite group of Gold Medal Moms who can ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. She ... is the nation’s leading networking organization exclusively for professional women, boasting more than 850,000 ...
(Date:11/30/2015)... ... 2015 , ... Being a caregiver for someone you love ... Care System, the Caregiver Support Program promotes the health and wellbeing of family ... percent report that their role as a caregiver has created marital strain,” said ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to research by ... require dental technicians to be certified or obtain continuing education. To increase awareness ... In Your Mouth?” campaign to inform dentists that the technicians they trust could ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Museum of Science & ... a new era of publicly accessible automated technology. Now, by popular demand, the ... guests an up-close look at the shuttle at MOSI’s main entrance. This experience ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... -- IBA Molecular North America, Inc. (IBAMNA), a U.S. leader ... as of January 1, 2016, it will do business ... rebrand the company reflects a refined vision for the ... relationship with Zevacor Molecular.  Both IBAMNA and Zevacor Molecular ... Peter Burke , Vice President Sales and ...
(Date:11/30/2015)... -- North America was valued at ... a CAGR of 7.6% from 2015 to 2020. --> ... in 2014, and is expected to grow at a CAGR of ... new Market Research Report "North America Cardiac Output Monitoring Devices Market ... care, others) - Analysis And Forecast To 2020", the cardiac output ...
(Date:11/30/2015)... 30, 2015  Kevin Smith has been appointed ... global pioneer in wireless monitoring of vital signs.  ... , Mr. Smith will be responsible for ... strategy.  He will also directly oversee partnering with ... evidence for SensiumVitals, the first early warning detection ...
Breaking Medicine Technology: